Friday, November 9, 2018

Agreement signed between LIF and Sayago Hospital

It is an agreement of “Mutual collaboration and assistance”. LIF will do health controls and monitoring to its employees. Santa Fe’s Health Ministry participated in the signature.


Andrea Uboldi (Santa Fe’s Health Ministry); Fabián Mendoza (Sayago Hospital’s Director); Jorge Stettler and Diego Bruno (LIF’s Directors) signed an agreement of “Mutual collaboration and assistance”.

The main objective will be to do health controls and monitoring on the LIF’s staff members. Production Area’s staff will be the first group of employees to start the controls.

“LIF and Sayago Hospital are neighbours and have had a long history of activities together. Doing these controls by the Public Health Service strengthens both institutions”, expressed Jorge Stettler.

“This is an innovative idea. We want to monitor the health of our workers and prevent possible diseases”, said Andrea Uboldi.

“Through the medical histories we can monitor the health of the workers and take preventive measures to avoid diseases in the future”, said Fabián Mendoza.

LIF visited by COSSPRA’s Authorities and Provincial Health Ministries

Some Health Ministries from different provinces and authorities of COSSPRA* visited LIF. They met with LIF’s Directors and explored the facilities. 




Some Health Ministries, Presidents and referents of public health insurances from different provinces such as: Tierra del Fuego, Chubut, Río Negro, Misiones, Entre Ríos, San Juan, Jujuy, Tucumán and Catamarca participated in this activity.

First, Andrea Uboldi (Santa Fe’s Health Ministry) welcomed the visitors.

Second, they met with LIF’s Board of Directors where they received information about public production of medicines and the different projects in progress.

After that, the group explored the different facilities with a guided tour.

Finally, the visitors, LIF’s Directors and staff members shared a lunch and exchanged their experiences.


*COSSPRA is the Provincial Federation of Social Health Insurance of Argentina.

Thursday, November 1, 2018

LIF will Develop Five New Medicines for Healthcare System

It will be through an agreement with the Pharmacy School (UNR*) and LAFEDAR S.A. (from Entre Ríos province). It will require $ 5 million (ARG) as initial investment.  
 
The main objective is to develop and produce five new medicines, such as: Atorvastatin 20 mg, Clarithromycin 500 mg, Losartan 50 mg, Metformin 850 mg (all of them in tablets) and Pediatric Ibuprofen 2% in syrup. At the beginning, these medicines will be delivered in the healthcare system of Santa Fe province.

Biochemistry and Pharmacy School of UNR, LAFEDAR S.A. and LIF will work to develop these medicines through this agreement. As a result of this, in fifteen months LIF will have the know how to produce them in its facilities.

Andrea Uboldi (Santa Fe’s Health Ministry), Jorge Stettler, Carlos Arques, Diego Bruno and Guillermo Cleti (LIF’s Boards of Directors) and Ricardo Guimarey (LAFEDAR S.A. Chief) signed the agreement.

“We celebrated this agreement between public and private institutions through which LIF will obtain the know how and technology to produce five new medicines. Due to this, more people will have a better access to chronic treatments in the healthcare system”, expressed Andrea Uboldi.

“Today, Santa Fe province is buying these five drugs. Through this agreement, LIF will be in perfect conditions to produce the medicines at LIF’s facilities from January 2020. A year and a half after that time, we hope to recover the initial investment of the project”, expressed Guillermo Cleti.

Horacio Coutaz (LIF’s Trustee) and Roberto Ganin (LIF’s General Manager) also participated in the meeting.

About the use of these drugs:

- Atorvastatin oral tablet is used to improve cholesterol levels and decrease your risk for heart attack and stroke.
- Losartan is used to treat high blood pressure (hypertension).
- Metformin is used to control high blood sugar. It is used in patients with type 2 diabetes.
- Clarithromycin is used to treat certain bacterial infections, such as pneumonia (a lung infection), bronchitis (infection of the tubes leading to the lungs), and infections of the ears, sinuses, skin, and throat.
- Pediatric Ibuprofen: it is analgesic and antipyretic.


*UNR: Universidad Nacional de Rosario.

Thursday, October 18, 2018

Members of IPAS Visited LIF

Two members of this international organization met with Directors and explored the facilities.


LIF’s Directors Jorge Stettler, Guillermo Cleti and Carlos Arques received Karen Padilla (Program Manager for IPAS Latin America) and Guillermo Ortíz (IPAS Advisor Physician).

They had a meeting where Leonardo Martínez (Subsecretary of Territorial Management of 1st and 2nd Level of Santa Fe´s Healthcare), Members of the Human Rights Secretary, CEMAFE*, Horacio Coutaz (LIF’s Trustee) and Roberto Ganin (LIF’s General Manager) also participated.

IPAS is an international organization focused on expanding access to safe abortion and contraceptive care, and to ending unsafe abortion.

“We are an international organization and work to promote the protection and respect the sexual and reproductive health as well as the women’s reproductive rights. We have a collaborative agreement with Santa Fe province to help and to give technical assistance to improve the abortion comprehensive care”, expressed Karen Padilla.

After meeting, the visitors could explore the different facilities.

*CEMAFE: Centro Médico Ambulatorio de Santa Fe (Outpatient Medical Center of Santa Fe)

Friday, October 5, 2018

LIF’s Directors Met with Ph.D. Dohyeong Kim from University of Texas in Dallas

He is a well-known researcher from Korea. Today, he works at the University of Texas. He met with Directors and explored the facilities.

 
LIF’s Board of Directors: Carlos Arques, Diego Bruno, Jorge Stettler and Guillermo Cleti; Horacio Coutaz, Trustee, and Roberto Ganin, General Manager welcomed Dohyeong Kim and had a meeting where they exchanged information about the public production of medicines, as well as the different researches that Kim has been making.

Dohyeong Kim specializes in administration, planning and public politics. He is Associate Professor at the University of Texas in Dallas. He has a Master´s degree in Public Administration and Planing, and a Doctorate in Urban Planning and Health Politics by the University of North Carolina.

After meeting, the visitor explored the facilities together with Roberto Ganin.

Monday, October 1, 2018

LIF Has Started to Provide Opioids to the National Government Again

Methadone and morphine for different hospitals around Argentina. Palliative care and public production of medicines: two firm state policies in Santa Fe province.

LIF provided a first amount of opioids to the National Government through an agreement with Instituto Nacional de Cáncer* (INC).

INC will distribute these medicines around the country in different hospitals with palliative care service.

Methadone 5 mg (150.000 tablets) and morphine 10 mg (1.150.000 tablets) were the amounts delivered by LIF. Before the end of the year, LIF must provide a similar quantity of these two drugs to complete the agreement.

It is important to highlight that this LIF’s production has a price between 30% and 50% of the cheaper one of the pharmaceutical market, and due to this, Santa Fe province contributes through this firm state policy to the national policies for fighting cancer.

The Banco Nacional de Drogas Oncológicas is the place where INC storages the medicines. Then, from there the drugs will be delivered to the different hospitals around the country.

This is the second stage of the Pilot Program to provide drugs for pain treatment in patients with active, progressive and advanced diseases.

The first stage was between 2014 and 2016. In that moment, LIF provided directly more than one million tablets (methadone and morphine) in different hospitals in Argentina.

*Instituto Nacional de Cáncer (INC): National Institute of Cancer.

Friday, August 24, 2018

LIF Is Already Providing Medicines for TB Treatments

Medicines for tuberculosis (TB) treatments were developed and produced in the new LIF’s area. Santa Fe is pioneer in this field and could solve the lack of medicines through their public production.

 
 
Few months after the inauguration of the new developed and production area, LIF has started producing medicines for tuberculosis (TB) treatments.

In the last two months, LIF has provided Santa Fe’s healthcare public system with 90.000 tablets of three drugs such as: Isoniazid 100 mg, Isoniazid 300 mg and Ethambutol 400 mg.

TB drugs are often provided by the National Health Ministry, but this activity was discontinued in the last months due to different issues in the last tender.

Santa Fe province could guarantee the access to the medicines for the patients through their public production.

“Today, LIF’s TB drugs production is a solution for Santa Fe province, but we will reach the national approval by ANMAT* and therefore we could have these drugs available for other provinces”, expressed Guillermo Cleti.

Rifampicin + Isoniazid (double combined tablet) and Rifampicin + Isoniazid + Pyrazinamide (triple combined tablet) are being processed by the typical stability studies. In view of this, the combined tablets will probably be available in the next year.

TB drugs production is an important progress for LIF, as well as an example of why it is necessary that the State has a tool like public production, and consequently gives a solution for the population so that they can access medicines.

*ANMAT: Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. (National Regulatory Agency for medicines, food and medical devices).